Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome

Spitzer, D; Wogatzky, Johannes; Murtinger, Maximilian; Zech, Mathias; Haidbauer, R.; Zech, Nicolas H.

doi:10.1016/j.fertnstert.2011.02.032

Cited by 21 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings remark the importance of prolactin in triggering the ovarian defects in this model. There are several studies showing that dopamine agonist therapy reduces the incidence of ovarian hyperstimulation syndrome in women at risk (45–47) and in hyperprolactinemic women with polycystic ovary syndrome undergoing assisted reproduction (48). This effect seems to be due to a deregulation of the dopaminergic tone and dopamine D 2 receptor signaling that affects the vascular permeability of the ovary (49, 50).…”

Section: Discussionmentioning

confidence: 99%

Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

et al. 2012

View full text Add to dashboard Cite

Female infertility is often associated with deregulation of hormonal networks, and hyperprolactinemia is one of the most common endocrine disorders of the hypothalamic-pituitary axis affecting the reproductive functions. We have shown previously that transgenic female mice overexpressing human chorionic gonadotropin β-subunit (hCGβ+ mice), and producing elevated levels of bioactive LH/hCG, exhibit increased production of testosterone and progesterone, are overweight and infertile, and develop hyperprolactinemia associated with pituitary lactotrope adenomas in adult age. In the present study, we analyzed the influence of the hyperprolactinemia of hCGβ+ females on their reproductive phenotype by treating them with the dopamine agonists, bromocriptine and cabergoline. Long-term bromocriptine treatment of adult mice was effective in the control of obesity, pituitary growth, and disturbances in the hormone profile, demonstrating that hyperprolactinemia was the main cause of the hCGβ+ female phenotype. Interestingly, short-term treatment (1 wk) with cabergoline applied on 5-wk-old mice corrected hyperprolactinemia, hyperandrogenism, and hyperprogesteronemia, prevented pituitary overgrowth, normalized gonadal function, and recovered fertility of adult hCGβ+ females after hormone-induced and natural ovulation. The same cabergoline treatment in the short term applied on 3-month-old hCGβ+ females failed to recover their reproductive function. Hence, we demonstrated that the short-term cabergoline treatment applied at a critical early stage of the phenotype progression effectively prevented the hyperprolactinemia-associated reproductive dysfunction of hCG-overproducing females.

show abstract

Section: Discussionmentioning

confidence: 99%

Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The study showed more than a 50% reduction in the incidence of moderate OHSS with the use of cabergoline from the day of hCG administration through six days post oocyte retrieval (135). Several other studies and metaanalyses have demonstrated similar fi ndings for cabergoline, as well as for the other dopamine agonists quinagolide and bromocriptine (136)(137)(138)(139)(140)(141)(142). Such novel options make pathophysiologic sense, and have the potential to play a future role in OHSS prevention.…”

Section: Dopamine Agonistsmentioning

confidence: 77%

Severe ovarian hyperstimulation syndrome

Levine¹,

Berin²,

Navot³

2012

Textbook of Assisted Reproductive Techniques, Volume Two: Clinical Perspectives

View full text Add to dashboard Cite

“…Another group performed an uncontrolled study on use of the same dose of bromocriptine in 44 patients at risk of OHSS after ovarian stimulation for IVF, also starting the day of oocyte retrieval (73). The oral route was chosen.…”

Section: The Association Between Dopamine Agonists and Vegfmentioning

confidence: 99%

Etiology of OHSS and use of dopamine agonists

Soares¹

2012

Fertility and Sterility

View full text Add to dashboard Cite

Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome

Cited by 21 publications

References 13 publications

Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

Short-Term Pharmacological Suppression of the Hyperprolactinemia of Infertile hCG-Overproducing Female Mice Persistently Restores Their Fertility

Severe ovarian hyperstimulation syndrome

Etiology of OHSS and use of dopamine agonists

Contact Info

Product

Resources

About